MYGN Quote, Financials, Valuation and Earnings

Intuitive Surgical, Inc. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 28.31%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 28.51%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 1.24%. Given that Myriad Genetics, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Myriad Genetics, Inc. is more attractive than Intuitive Surgical, Inc..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 78.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.74x versus 22.40x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neogen Corp. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 17.37%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Neogen Corp.'s return on equity of -41.21%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 28.51%. On the other hand Neogen Corp. has an analysts' consensus of $8.17 which suggests that it could grow by 10.66%. Given that Myriad Genetics, Inc. has higher upside potential than Neogen Corp., analysts believe Myriad Genetics, Inc. is more attractive than Neogen Corp..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison Neogen Corp. has a beta of 1.956, suggesting its more volatile than the S&P 500 by 95.564%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Neogen Corp. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Neogen Corp. quarterly revenues of $209.2M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Neogen Corp.'s net income of $36.3M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Neogen Corp.'s PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.74x versus 1.81x for Neogen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 12.4%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Insulet Corp.'s return on equity of 18.92%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 28.51%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 26.26%. Given that Myriad Genetics, Inc. has higher upside potential than Insulet Corp., analysts believe Myriad Genetics, Inc. is more attractive than Insulet Corp..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.400, suggesting its more volatile than the S&P 500 by 39.975%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Insulet Corp.'s net income of $87.6M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 86.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.74x versus 8.59x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Repligen Corp. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 7.9%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Repligen Corp.'s return on equity of 0.09%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 28.51%. On the other hand Repligen Corp. has an analysts' consensus of $189.22 which suggests that it could grow by 11.93%. Given that Myriad Genetics, Inc. has higher upside potential than Repligen Corp., analysts believe Myriad Genetics, Inc. is more attractive than Repligen Corp..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.925%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are larger than Repligen Corp. quarterly revenues of $188.8M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Repligen Corp.'s net income of $14.9M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Repligen Corp.'s PE ratio is 6,552.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.74x versus 13.47x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.